Digital
healthcare industry is drawing attention as non-face-to-face became a
commonplace due to COVID-19 pandemic passes through a long term. According to
Global Market insights, a market research institute, the size of the digital
healthcare market is expected to grow 29.6% annually from 106.4 billion (about
127 trillion won) in 2019, reaching $504.4 billion (about 603 trillion won) in
2025.
Especially,
the main issue is the expansion of infrastructure through blockchain
technology. If block chain technology can be used in digital healthcare
industry, not only collected data can be managed safely and transparently, but
also it is possible to create a circumstance where patients themselves can have
right to control over their data.
Focusing
on the core keyword ‘Immunity,’ NKCL Bio Group is a bio incorporation that
researches and develops NK cell treatment and Immune care products that can
help improve immunity. In addition to the development and production of NK cell
treatment through its own technology, it is expanding production facility lines
to enter the market of CDMO, Contract Manufacturing Organization (CMO) and Contract
Development Organization (CDO), which is expected to grow from 13.3 billion
dollars’ worth of size in 2020, and over 13.7% grow annually.
NKCL
Bio Group set automated cultivation system where artificial intelligence (AI)
applied. Specially programmed AI can find the best cultivate environment for NK
cell cultivation, so not only it replaced existing high-quality manpower, but
also achieved improved production efficiency over 100 times and more.
GMP
Automated Cultivation System operates and enables cultivate within a closed
system throughout the entire process. Blocking any sources of contamination,
the mass production of NK Cell is possible and evaluated to maximize the price
reduction by reducing labor costs and production costs. It is expected to
increase potential customers and expanding immune cell treatment market by facilitating
NK cell treatment easily accessible. Moreover, global popularization can be
achieved by exporting automated cultivation system solutions and plants.
Because
NKCL Bio Group is leading popularization of NK cell treatment, NKCL
Bio-Blockchain is getting attention from the industry. NKCL Bio Group is
constructing blockchain technology based personal bio-data platform, NKCL Bio
Blockchain. It operates and records cultivation history, usage history and
clinical results of NK Immune cell automated cultivation on the blockchain
NKCL
Bio-Blockchain is designed in a dual structure. Customer’s bio-data are safe,
manage and operate better by recorded in private blockchain where requires
separate authentication and only qualified participants can participate and
enable to access, not on the public blockchain where anyone can access and
check the details.
Medical
providers, such as medical institutions and pharmaceutical companies can
contribute to medical development that includes patients customized care, research
and development through related bio-data.
The
issue in the medical and bio big data industries is the connection of data
standardization and data providing medical institution.
An
official from NKCL emphasizes that this is the competitivities of NKCL platform.
As an explanation, NKCL Bio-Blockchain works for bio data that are produced in
the NKCL Platform internally, it is unnecessary to depend on medical
institutions, which are comparatively positioning in higher position, and
enable to use standard data of itself.
An
official from NKCL, expressing ambition, said, “Due to COVID-19, the importance
of immunity is well emphasized these days. It is our goal to achieve
competitiveness of NKCL Bio-blockchain by expanding the non-face-to-face
medical service range through enforcing data protection and creating high added
value by data collection and integration.”